WO2005034930A1 - Granules contenant du chlorhydrate de venlafaxine - Google Patents

Granules contenant du chlorhydrate de venlafaxine Download PDF

Info

Publication number
WO2005034930A1
WO2005034930A1 PCT/HU2004/000095 HU2004000095W WO2005034930A1 WO 2005034930 A1 WO2005034930 A1 WO 2005034930A1 HU 2004000095 W HU2004000095 W HU 2004000095W WO 2005034930 A1 WO2005034930 A1 WO 2005034930A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight
pellets
venlafaxine hydrochloride
pelletization
sodium chloride
Prior art date
Application number
PCT/HU2004/000095
Other languages
English (en)
Inventor
Pál FEKETE
Tibor KORBÉLY
Ágnes BOZSÓ
Eszter MÓRICZ
Original Assignee
EGIS Gyógyszergyár Rt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to UAA200605099A priority Critical patent/UA82268C2/uk
Priority to CN2004800330326A priority patent/CN1882321B/zh
Application filed by EGIS Gyógyszergyár Rt. filed Critical EGIS Gyógyszergyár Rt.
Priority to RS20060252A priority patent/RS52150B/en
Priority to SK5044-2006A priority patent/SK50442006A3/sk
Priority to YUP-2006/0252A priority patent/RS20060252A/sr
Priority to SI200430364T priority patent/SI1677777T1/sl
Priority to EA200600675A priority patent/EA009695B1/ru
Priority to DK04791654T priority patent/DK1677777T3/da
Priority to EP04791654A priority patent/EP1677777B1/fr
Priority to AU2004280132A priority patent/AU2004280132B2/en
Priority to PL04791654T priority patent/PL1677777T3/pl
Priority to DE602004006009T priority patent/DE602004006009T2/de
Publication of WO2005034930A1 publication Critical patent/WO2005034930A1/fr
Priority to IL174830A priority patent/IL174830A/en
Priority to HR20060136A priority patent/HRP20060136A2/xx
Priority to NO20062082A priority patent/NO20062082L/no
Priority to HK07104778.3A priority patent/HK1098364A1/xx
Priority to CY20071100874T priority patent/CY1106693T1/el
Priority to HR20070322T priority patent/HRP20070322T3/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Definitions

  • the invention relates to pellets containing venlafaxine hydrochloride and a process for the preparation thereof.
  • Venlafaxine (1- [2- (dimethylamino) -1- (4-methoxy- phenyl) ethyl] cyclohexanol) is a highly important antidepressant belonging to the antipsychotics possessing serotonin/noradrenalin uptake inhibiting effect (SNRI) .
  • SNRI serotonin/noradrenalin uptake inhibiting effect
  • a drawback of immediate release pharmaceuticals in therapeutic application resides in the fact that the quick release of the active agent results in a high plasma concentration, which causes unpleasant side-effects, such as nausea or vomiting in a considerable part of the patients .
  • the administration of sustained release pharmaceutical dosage forms is very advantageous, because the slow release of the active ingredient results in a lower and even blood level and thus the side-effects can be decreased.
  • sustained release pharmaceutical dosage forms are pharmaceuticals containing drug-loaded pellets.
  • Pellets are spherical agglomerates 0,2-2 mm in diameter, which may be coated with one or more layer (s) regulating the release of the active agent and filled into hard gelatine capsules or tabletted
  • the capsules or tablets are disintegrated or distributed into individual pellets, which are then thoroughly mixed with the content of the stomach, and the discharge of the pellets from the stomach becomes more uniform.
  • a high active agent concentration cannot develop during the release of the active ingredient from the pellets , thus the plasma concentration becomes more even.
  • the therapeutic activity of the composition becomes more favourable and the likelihood of the occurrence of side-effects considerably decreases .
  • the first pellet-based pharmaceutical compositions were put on the market m the early 1950s. However, they could not become more widespread until the 1970s due to their cumbersome preparation technology, which was based on the layering of the active ingredient and solid auxiliary agents, such as various types of starch, onto sugar crystals in coating drums, and in this way the pellet preparation took several days .
  • Pellets can be prepared according to a number of methods, which all can be based on the following tree principles:
  • a mixture of the particles of the active ingredient and/or the auxiliary agents of small particle size is applied in layers onto a nearly lsodiamet ⁇ c seed material having larger particle size than that of the said active ingredient and/or auxiliary agents.
  • the application can be performed in a conventional coating drum, in a centrifugal granulating equipment or in a fluidization spraying apparatus.
  • the active ingredient can be sprayed onto the surface of the inert granules from a solution.
  • the high solubility (exceeding 600 mg/ml) of the active ingredient is disadvantageous from the viewpoint of the layering pelletization.
  • the active ingredient is mixed with the auxiliary agents and a liquid, the wet mass is fed into an extruder having holes of about 1 mm in diameter, and the extrudate is formed into uniform, nearly spherical particles in a rotary spheronization machine.
  • a mixture of the active ingredient and the auxiliary agents is mixed in a mixer or in a centrifugal or fluidization granulator, while a liquid is fed into the machine.
  • the particles of the powder mixture adhere to each other and become spherical upon the ef ect of shear forces and abrasive forces .
  • the last step of all pelletization processes is drying of the particles and separation of the fraction having a particle size suitable for further processing, .
  • the quality of the pelletization technology can be characterized by the product fraction, that is by the ratio of the mass of the pellets having the desired particle size to the total mass of the pellets.
  • the pellets of unsuitable size are namely recycled to the manufacturing process and processed repeatedly, which results in an increase of the production time, costs of material and energy and the intensity of the labour involved in the procedure.
  • the preferable particle size varies between 0.5 mm and 1.0 mm, in case of pellets compressed into tablets between 0.3 mm and 0.6 mm.
  • active ingredients readily soluble in water it is expedient to use pellets of bigger particle size, such as 0.8 - 1.6 mm or 1.0 - 2.0 mm, in order to . decrease the amount of the coating material necessary for the coating modifying the release of the active ingredient.
  • excipients are also applied for the pelletization, which promote the formation of pellets of appropriate shape and surface.
  • excipients may be fillers, lubricants, antiadhesives , disintegrants or drug release promoting additives, buffers, surfactants, surface-active substances, pelletiz- ation promoting additives or glidants (Isaac Ghebre-Sellassie : Pharmaceutical Pelletization Technology, Marcel Dekker, Inc., New York, Basel , 1989) .
  • fillers which can be used for the pelletization e.g. calcium sulfate, calcium hydro- phosphate, lactose, mannitol, szaccharose, starch and microcrystalline cellulose are mentioned.
  • Suitable binders are e.g. gelatine, hydroxy-propyl cellulose, hydroxypropyl-methyl cellulose, methylcellulose, polyvinyl pyrrolidone, szaccharose and starch.
  • As lubricant calcium stearate, hydrogenated vegetable oil, magnesium stearate, mineral oil, polyethylene glycol , glycerine and propylene glycol may be applied.
  • the pellets may also contain antiadhesives, such as kaolin, talk or silicon dioxide, furthermore disintegrants or drug release promoting agents, e.g. alginates, sodium carboxymethyl cellulose, crospovidon, starch, pre-gelatinized starch, sodium carboxymethyl starch, or e.g. ethyl- cellulose, carnauba vax, shellac.
  • Antiadhesives such as kaolin, talk or silicon dioxide
  • furthermore disintegrants or drug release promoting agents e.g. alginates, sodium carboxymethyl cellulose, crospovidon, starch, pre-gelatinized starch, sodium carboxymethyl starch, or e.g. ethyl- cellulose, carnauba vax, shellac.
  • Buffers such as citrate, phosphate, carbonate and hydro- carbonate salts
  • surface-active additives such as polysorbate, sodium laurylsulfate
  • spheronization promoting substances
  • micro- crystalline cellulose or a mixture of micro- crystalline cellulose and sodium carboxymethyl cellulose may also be used for the pellets.
  • Glidants applied during pelletization include e.g. colloidal silicon dioxide, magnesium stearate, talc and starch.
  • the ratio of the product fraction is about 60% by weight. That is why every technical solution resulting in an increase in the product fraction in addition to the maintenance of other important characteristics of the pellets - such as a nearly spherical shape and a suitable quality of the surface - is of high importance.
  • pelletization is a complicated pharmaceutical operation requiring a special equipment and intensive labour.
  • Venlafaxine hydrochlorj de belongs to the group of the active ingredients readily soluble in water (0.57 g/ml) .
  • Hungarian patent application No. P9700589 suggests that in case of venlafaxine hydrochloride having a solubility higher than 500 mg/ml pelletization can be performed only by the application of microcrystalline cellulose combined with hydroxypropyl-methyl cellulose.
  • pellets containing venlafaxine can also be prepared without the application of hydroxypropyl-methyl cellulose if the ratio of the weight of venlafaxine is decreased in the pellets.
  • this solution is unfavourable, because in case of identical doses a decrease in the weight ratio of venlafaxine constitutes a higher pellet weight and consequently a medicine of bigger size. Thus it is more difficult to swallow the composition and the manufacture is more expensive.
  • the aim of the invention was to elaborate a composition and process which are suitable for the preparation of pellets in up-to-date fluidization and rotogranulation machines providing the preparation of the product fraction (that is the ratio of pellets used for further processing) in a high yield, that is in a yield of at least 75%, preferably more that 80%, and in a suitable quality.
  • the invention is based on the surprising recognition that if 10 to 60% by weight of sodium chloride and/or potassium chloride are added to the powder mixture to be pelletized in addition to at most 80% by weight of active agent and 10 to 60% by weight of microcrystalline cellulose, pellets with high active ingredient content and very advantageous in shape (approximately spherical) can be produced from the otherwise unpelletizable active agents as well. Besides, the particle size of the said pellets is highly suitable for pharmaceutical purposes, and the yield of the product fraction exceeds 75% .
  • nearly spherical pellets comprising the pharmaceutical ingredient venlafaxine hydrochloride in admixture with 10 to 60% by weight of sodium chloride and/or potassium chloride and 10 to 60% by weight of microcrystalline cellulose and optionally other, pharmaceutically acceptable excipipents and/or additives promoting the pelletization.
  • a process for the preparation of nearly spherical pellets containing the pharmaceutical ingredient venlafaxine which comprises admixing at most 80% of the active ingredient with 10 to 60% by weight of microcrystalline cellulose, 10 to 60% by weight of sodium chloride and/or potassium chloride and optionally other, pharmaceutically acceptable excipients and/or additives promoting the pelletization, converting the thus-obtained mixture into pellets by high-shear mixing, rotofluidization or extrusion-spheronization method, preferably by rotofluidization by spraying water or preferably an aqueous dimethyl polysiloxane emulsion and/or an aqueous solution of xanthane gum, drying the pellets, separating the desired product fraction and optionally coating the pellets with a layer to modify the drug release.
  • dimethyl polysiloxane is emulged in the pelletizmg liquid. In this way the particle size of the thus-obtained pellets can be controlled much better, the size or the pellets is more uniform and the product fraction may exceed even 90%. Similar results can be achieved when xanthane gum is dissolved in the pelletezing liquid, or when the pelletizing liquid contains both dimethyl polysiloxane and xanthane gum.
  • the pharmaceutical compositions containing pelletized active ingredient are usually prepared in dosage unit forms. During the pelletization process the concentration of the active ingredient is determined by the single dose of the active agent finished in a dose unit so that the weight of the pellets containing a single dose of the active ingredient should vary between 50 to 1500 mg, preferably between 100 to 700 mg.
  • the sodium chloride and/or potassium chloride and microcrystalline cellulose content of the pellet can be determined.
  • the premix used for the preparation of pellets according to the invention possessing advantageous properties should contain a total amount of at least 10% by weight of both excipients. If the active ingredient content of the pellets is lower than 80% by weight as a consequence of a lower dose, the sodium chloride and/or potassium chloride and microcrystalline cellulose content may be increased.
  • the two types of excipients can be used in nearly identical amounts .
  • microcrystalline cellulose used for the preparation of pellets according to the invention
  • quality of the microcrystalline cellulose used for the preparation of pellets according to the invention there are no restrictions.
  • Various types of microcrystalline cellulose of different particle size and oS different density may freely be applied. Even the application of microcrystalline cellulose with a low moisture content is not required, since during pelletization the substance mixture is moistened with water or contacted with an aqueous solution or dispersion.
  • mixtures of various types of microcrystalline cellulose formed with colloidal silicon dioxide can also be used, which contain about 98% by weight of microcrystalline cellulose and about 2% by weight of colloidal silicon dioxide.
  • both sodium chloride and potassium chloride can be used to advantage, but due to their different physiological effects it is preferable to chose their concentrations on the basis of the extracellular physiological concentration.
  • choosing e.g. 10% by weight as sodium chloride/potassium chloride concentration, preferably 9.5% by weight of sodium chloride and 0.5% by weight of potassium chloride can be applied.
  • the quality of the pellets and the quantity of the amount of pellets falling into the preferable particle size region can be improved.
  • xanthane gum or dimethyl polysiloxane may be used.
  • These auxiliary agents are dissolved or disperged either individually or together in water used for the pelletization, and added to the premix to be pelletized in the beginning of the pelletization procedure.
  • Xanthane gum used in the compositions according to the invention is a natural polysaccharide produced by the microorganism Xantomonas campestr ⁇ s .
  • the skeleton of xanthane gum such as 'that of cellulose,- consints of 1,4-gluco- pyranose units, while the side-chains contain mannose, acetate and glucuronic acid.
  • the average molecular weight is a few million Dalton.
  • xanthane gum is mostly applied for increasing the stability of suspensions used for coating of medicines or films (e.g. Hungarian patent specification No. 202120) or as a viscosity-increasing agent (the United States Pharmacopoeia, ed. 26., 2003, United States Pharmacopoeial Convention, Inc, Rockwille, USA) or as a matrix building material for extended release tablets .
  • xanthane gum increases the stability of the pellets. This advantageous effect of this substance has not so far been mentioned in the literature and could not be aforeseen.
  • Xanthane gum can be used in the pelletization liquid in an amount of not exceeding 2% by weight related to the final weight of the pellet.
  • Dimethyl polysiloxane used in the compositions according to the invention is a liquid substance, a completely methylated polymeric siloxane having a viscosity value between 100 and 1000 centi-stokes .
  • the aqueous dimethyl polysiloxane dispersions are commercially available products, which are used for surface treatments, as skin softening additives for pharmaceutical and cosmetic compositions, as antifriction agents for tabletting or as antiadhesives for film-coating (Hungarian patent specification No. 190,693).
  • the United States Pharmacopoeia USP 26 classifies dimethyl polysiloxane into the group of antifoam additives.
  • a surprising - and so far fully unknown - property of dimethyl polysiloxane is that in the course of pelletization, when emulged in an amount of not exceeding 5% by weight into water or an aqueous colloidal solution of xanthane gum used for the pelletization, it improves the spherical shape of the pellets and augments the ratio of the product fraction.
  • the pellets according to the invention can be prepared by build-up (high-shear or rotofluidization) or by extrusion-spheronization methods known from the literature.
  • venlafaxine hydrochloride is mixed with sodium chloride and/or potassium chloride and microcrystalline cellulose
  • the mixture is homogenized and the thus-obtained powdered premix is moistened with water or with an aqueous solution of the binder (s) and/or other, pharmaceutically acceptable excipients.
  • the mixture is converted into pellets of the desired particle size by using an appropriate equipment (extruder- spheronizator-d ⁇ er , high-shear granulator- drier, rotofluidization apparatus).
  • the product fraction having the desired particle size is isolated by size, e.g. by sieving.
  • the pellet fraction having an unsuitable particle size is transferred back to the pelletization process after grinding.
  • the pellets containing venlafaxine hydrochloride according to the invention are particularly suitable for further coating operations.
  • water-soluble e.g. hydroxypropyl-methyl cellulose, polyvmyl alcohol
  • water-insoluble e.g. ethyl cellulose, ethyl acrylate - methyl m thacrylate copolymer, poly- vinyl acetate
  • film-forming substances having a sulubility depending on the pH of the aqueous medium e.g. cellulose acetate phralate, hydroxypropyl-methyl cellulose acetate succinate, ethyl-acrylate-methacrylic acid copolymer
  • cellulose acetate phralate hydroxypropyl-methyl cellulose acetate succinate
  • ethyl-acrylate-methacrylic acid copolymer can equally be used.
  • Coating can be carried out with an aqueous or organic solution or an aqueous dispersion of the film-forming substances.
  • immediate release water-soluble coating
  • extended release water-insoluble coating
  • delayed release the solubility of the coating depends on the pH of the releasing medium compositions can be prepared.
  • the quality and quantity of the coating substance are to be determined on the basis of the dissolution profile, that is the desired dependence of the release on time.
  • pellets containing venlafaxine hydrochloride according to the invention and preparation thereof are illustrated by the following examples without limiting the scope of protection to said examples.
  • venlafaxine hydrochloride 396 g of microcrystalline cellulose, 6 g of colloidal silicon dioxide, 342 g of sodium chloride and 18 g of potassium chloride were mixed in an acid- resistant vessel.
  • the mixture was transferred to a fluidization rotogranulator (Glatt GPCGl) , and a mixture of 20 g of 35% dimethyl polysiloxane emulsion and 1000 ml of ion-exchanged water was sprayed onto it.
  • Spraying speed of the pelletiz- ing liquid was set at 50 ml/min, pressure of the spraying air was 2.5 bar.
  • the speed of the rotor was set at 450 rev/min in the first 15 minutes of the pelletization and later kept at 600 rev/min.
  • Speed by volume of the fluidization air was kept at 60 m 3 /hour in the first 15 minutes of the pelletization and later at 90 m 3 /hour.
  • the temperature of the fluidization air was set at 25 °C in the first part of the pelletization and to 40 °C for the drying procedure.
  • the dried pellets were passed through sieves having hole widths of 0,8 mm and 1,6 mm, respectively and divided into 3 fractions.
  • the product fraction that is the amount of the granules in the range between 0.8 mm and 1.6 mm, amounts to 96% by weight.
  • a fluidization apparatus of Glatt GPCGl type was equipped ' with a bottom spraying Wurster insert, and 500 g of the product fraction were fed into the container.
  • As coating liquid 200.0 g of an aqueous polymeric dispersion containing 30% of polyvinyl acetate (trademark name: Kollicoat SR) were applied.
  • To the said dispersion 8.4 g of propylene glycol dissolved in 240 g of water were added. Coating was carried out under the following conditions: - temperature of the fluidization air: 60 °C
  • venlafaxine hydrochloride 396 g of microcrystalline cellulose, 6 g of colloidal silicon dioxide, 342 g of sodium chloride and 18 g of potassium chloride were mixed in an acid- proof vessel .
  • the mixture was transferred to a fluidization rotogranulator (Glatt GPCGl), and a solution of 2 g of xanthane gum in 300 ml of ion-exchanged water and further 1080 ml of ion- exchanged water were sprayed onto it.
  • Spraying speed of the pelletizing liquid was set at 50 ml/min, pressure of spraying air was 2.5 bar.
  • the speed of the rotor was set at 450 rev/rnin in the first 15 minutes of the pelletization and later kept at 600 rev/mm.
  • Speed by volume of the fluidization air was kept at 60 m 3 /hour in the first 15 minutes of the pelletization and later at 90 m 3 /hour.
  • the temperature of the fluidization air was set at 25 °C in the first part of the pelletization and to 40 °C for the drying procedure.
  • the dried pellets were passed through sieves having hole widths of 1.6 mm and 0.8 mm, respectively and divided into three fractions.
  • the product fraction that is the amount of the pellets in the range between 0.8 mm and 1.6 mm, amounts to 90% by weight.
  • venlafaxine hydrochloride 396 g of microcrystalline cellulos, 6 g of colloidai silicon dioxide, 342 g of sodium chloride and 18 g of potassium chloride were mixed in an acid- proof vessel .
  • the mixture was transferred to a fluidization rotogranulator (Glatt GPCGl) , and a mixture of a solution of 2 g of xanthane gum in 250 ml of ion-exchanged water and 50 g of 35% dimethyl polysiloxane and a mixture of further 60 g of 35% dimethyl polysiloxane and 1000 ml of ion-exchanged water were sprayed onto it.
  • Gelatt GPCGl fluidization rotogranulator
  • Spraying speed of the pelletizing liquid was set at 50 ml/min, pressure of spraying air was 2.5 bar.
  • the speed of the rotor was set at 450 rev/min in the first 15 minutes of the pelletization and later kept at 600 rev/min.
  • Speed by volume of the fluidization air was kept at 60 m 3 /hour in the first 15 minutes of the pelletization and later at 90 m 3 /hour.
  • the temperature of the fluidization air was set at 25 °C in the first part of the pelletization and to 40 °C for the drying procedure.
  • the dried pellets were passed through sieves, having hole widths of 1.6 mm and 0.8 mm, respectively and divided into 3 fractions .
  • the product fraction that is the amount of the. granules in the range between 0.8 mm and 1.6 mm, amounts to 88.3% by weight.
  • a fluidization apparatus of Glatt GPCGl type is equipped with a bottom spraying Wurster insert, and 500 g of the above product fraction were fed into the container.
  • As coating liquid a solution of 60.0 g of ethylcellulose (viscosity: 10 centipoise) and 6.0 g of copovidone (vinylpyrrolidone acetate (60/40) co- polymer) in 550.0 g of 96% by volume ethanol were used, in which 18.0 g of talc had been suspended as antiadhesive. Coating was carried out under the following conditions:
  • venlafaxine hydrochloride 396 g of microcrystalline cellulose, 6 g of colloidal silicon dioxide, 342 g of sodium chloride and 16 s g of potassium chloride were mixed in an acid- proof vessel .
  • the mixture was transferred to a fluidization rotogranulator (Glatt GPCGl) , and 1500 ml of ion-exchanged water were sprayed onto it.
  • Spraying speed of the pelletizing liquid was set at 50 ml/min, pressure of spraying air was 2.5 bar.
  • the speed of the rotor was set at 450 rev/min in the first 15 minutes of the pelletization and later kept at 600 rev/min.
  • Speed by volume of the fluidization air was kept at 60 m 3 /hour in the first 15 minutes of the pelletization and later at 90 m 3 /hour .
  • the temperature of the fluidization air was set at
  • the dried pellets were passed through sieves having hole widths of 1.6 mm and 0.8 mm, respectively, and divided into 3 fractions.
  • the product fraction that is the amount of the granules in the range between 0.8 mm and 1.6 mm, amounts to 75.3% by weight.
  • the sieved substance was transferred to a fluidization rotogranulator of Glatt GPCG15 type, about 20 kg of ion-exchanged water were sprayed onto it and converted into pellets having a particle size mostly in the range between 0.-8 mm and 1.6 mm.
  • Spraying speed of the pelletizing liquid was set at 250 ml/min, pressure of spraying air was 3.5 bar.
  • the speed of the rotor was kept at 300 rev/min during the pelletization and at 500 rev/min during drying of the pellets.
  • Speed by volume of the fluidization air was varied between 350 and 750 m 3 /hour depending on the motion of the material .
  • the temperature of the fluidization air was kept at 25 °C during the pelletization and at 40 °C in the course of the drying.
  • a fluidization apparatus of Glatt GPCGl type was equipped with a bottom spraying Wurster insert, and 20 kg of the above product fraction were fed into the container.
  • As coating liquid a solution of 3.30 kg g of ethylcellulose (viscosity: 10 centipoise) and 0.33 kg of copovidone (vinylpyrrolidone/vinylacetate (60/40) copolymer) in 30 kg of 96% by volume ethanol was used, in which as antiadhesive 0.99 kg of talc and as colouring agent 0.02 kg of iron oxide pigment had been suspended. Coating was carried out under the following conditions:

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des granulés contenant du chlorhydrate de venlafaxine et leur procédé de préparation. Ces granulés sont quasiment sphériques et contiennent 80 % en masse, tout au plus, de chlorhydrate de venlafaxine de qualité pharmaceutique, 10 à 60 % en masse de chlorure de sodium et/ou de potassium, 10 à 60 % en masse de cellulose microcristalline et éventuellement d'autres excipients et/ou additifs favorisant l'agrégation de qualité pharmaceutique. Ces granulés sont tout particulièrement conçus pour être enduits d'une couche assurant une libération contrôlée de l'ingrédient actif.
PCT/HU2004/000095 2003-10-10 2004-10-08 Granules contenant du chlorhydrate de venlafaxine WO2005034930A1 (fr)

Priority Applications (18)

Application Number Priority Date Filing Date Title
UAA200605099A UA82268C2 (uk) 2003-10-10 2004-08-10 Гранули, що містять гідрохлорид венлафаксину, та спосіб їх виготовлення
AU2004280132A AU2004280132B2 (en) 2003-10-10 2004-10-08 Pellets containing venlafaxine hydrochloride
EP04791654A EP1677777B1 (fr) 2003-10-10 2004-10-08 Granules contenant du chlorhydrate de venlafaxine
SK5044-2006A SK50442006A3 (sk) 2003-10-10 2004-10-08 Pelety obsahujúce hydrochlorid venlafaxínu
YUP-2006/0252A RS20060252A (en) 2003-10-10 2004-10-08 Pelletes containing venlafaxine hydrochloride
SI200430364T SI1677777T1 (sl) 2003-10-10 2004-10-08 Peleti, ki vsebujejo venlafaksin hidroklorid
EA200600675A EA009695B1 (ru) 2003-10-10 2004-10-08 Гранулы, содержащие гидрохлорид венлафаксина
DK04791654T DK1677777T3 (da) 2003-10-10 2004-10-08 Pellets indeholdende venlafaxin-hydrochlorid
RS20060252A RS52150B (en) 2003-10-10 2004-10-08 PELLETS CONTAINING VENLAFAKSIN HYDROCHLORIDE
CN2004800330326A CN1882321B (zh) 2003-10-10 2004-10-08 包含盐酸文拉法辛的小丸
DE602004006009T DE602004006009T2 (de) 2003-10-10 2004-10-08 Pellets mit venlafaxin-hydrochlorid
PL04791654T PL1677777T3 (pl) 2003-10-10 2004-10-08 Granulki zawierające chlorowodorek venlafaxiny
IL174830A IL174830A (en) 2003-10-10 2006-04-06 Pellets containing venlafaxine hydrochloride, pharmaceutical compositions comprising them and processes for their preparation
HR20060136A HRP20060136A2 (en) 2003-10-10 2006-04-07 Pellets containing venflaxine hydrochloride
NO20062082A NO20062082L (no) 2003-10-10 2006-05-09 Pellets inneholdende venlafaksinhydroklorid
HK07104778.3A HK1098364A1 (en) 2003-10-10 2007-05-04 Pellets containing venlafaxine hydrochloride
CY20071100874T CY1106693T1 (el) 2003-10-10 2007-07-02 Πελετες οι οποιες περιεχουν υδροχλωρικη βενλαφαξινη
HR20070322T HRP20070322T3 (en) 2003-10-10 2007-07-16 Pellets containing venlafaxine hydrochloride

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0303382A HUP0303382A2 (hu) 2003-10-10 2003-10-10 Venlafaxin-hidroklorid-tartalmú pelletek
HUP0303382 2003-10-10

Publications (1)

Publication Number Publication Date
WO2005034930A1 true WO2005034930A1 (fr) 2005-04-21

Family

ID=90001704

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2004/000095 WO2005034930A1 (fr) 2003-10-10 2004-10-08 Granules contenant du chlorhydrate de venlafaxine

Country Status (23)

Country Link
EP (1) EP1677777B1 (fr)
CN (1) CN1882321B (fr)
AT (1) ATE359771T1 (fr)
AU (1) AU2004280132B2 (fr)
BG (1) BG109539A (fr)
CY (1) CY1106693T1 (fr)
CZ (1) CZ2006269A3 (fr)
DE (1) DE602004006009T2 (fr)
DK (1) DK1677777T3 (fr)
EA (1) EA009695B1 (fr)
ES (1) ES2285538T3 (fr)
HK (1) HK1098364A1 (fr)
HR (2) HRP20060136A2 (fr)
HU (1) HUP0303382A2 (fr)
IL (1) IL174830A (fr)
NO (1) NO20062082L (fr)
PL (2) PL1677777T3 (fr)
PT (1) PT1677777E (fr)
RS (2) RS52150B (fr)
SI (1) SI1677777T1 (fr)
SK (1) SK50442006A3 (fr)
UA (1) UA82268C2 (fr)
WO (1) WO2005034930A1 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007135470A1 (fr) * 2006-05-19 2007-11-29 EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság Procédé de préparation et de revêtement de surface de granulés
EP1906935A2 (fr) * 2005-07-28 2008-04-09 Dr. Reddy's Laboratories Ltd. Compositions de venlafaxine à diffusion étendue
WO2011143119A1 (fr) * 2010-05-11 2011-11-17 Cima Labs Inc. Formes pharmaceutiques à libération prolongée résistantes aux alcools comprenant de la venlafaxine
US8062666B2 (en) 2001-11-13 2011-11-22 Lycored Bio Ltd. Extended release compositions comprising as active compound venlafaxine hydrochloride
WO2014096124A1 (fr) * 2012-12-19 2014-06-26 Ratiopharm Gmbh Granules revêtus d'un film
US8927025B2 (en) 2010-05-11 2015-01-06 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended-release oral dosage forms
US8951555B1 (en) 2000-10-30 2015-02-10 Purdue Pharma L.P. Controlled release hydrocodone formulations
US8975273B2 (en) 1999-10-29 2015-03-10 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9216176B2 (en) 2006-09-15 2015-12-22 Cima Labs Inc. Abuse resistant drug formulation
US9707224B2 (en) 2013-10-31 2017-07-18 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
CN114028577A (zh) * 2021-10-20 2022-02-11 珠海市东辰制药有限公司 一种二氧化硅丸芯及其制备方法
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11992468B2 (en) 2019-05-07 2024-05-28 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103893151B (zh) * 2012-12-31 2018-04-27 石药集团中奇制药技术（石家庄）有限公司 一种盐酸文拉法辛缓释胶囊及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003041692A1 (fr) * 2001-11-13 2003-05-22 Karma Pharm Ltd. Compositions a liberation prolongee comprenant du chlorhydrate de venlafaxine utilise en tant que compose actif
EP1331003A1 (fr) * 1996-03-25 2003-07-30 Wyeth Composition de venlafaxine à libération prolongée
WO2003082261A1 (fr) * 2002-03-28 2003-10-09 Synthon B.V. Formulations de venlafaxine a liberation prolongee

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
UA77145C2 (en) * 1997-11-05 2006-11-15 Wyeth Corp Extended release dosage formulation
CN1334080A (zh) * 2001-07-25 2002-02-06 成都康弘制药有限公司 盐酸万拉法新缓释片及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1331003A1 (fr) * 1996-03-25 2003-07-30 Wyeth Composition de venlafaxine à libération prolongée
WO2003041692A1 (fr) * 2001-11-13 2003-05-22 Karma Pharm Ltd. Compositions a liberation prolongee comprenant du chlorhydrate de venlafaxine utilise en tant que compose actif
WO2003082261A1 (fr) * 2002-03-28 2003-10-09 Synthon B.V. Formulations de venlafaxine a liberation prolongee

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8975273B2 (en) 1999-10-29 2015-03-10 Purdue Pharma L.P. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US10076516B2 (en) 1999-10-29 2018-09-18 Purdue Pharma L.P. Methods of manufacturing oral dosage forms
US9675611B1 (en) 1999-10-29 2017-06-13 Purdue Pharma L.P. Methods of providing analgesia
US9669022B2 (en) 1999-10-29 2017-06-06 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9669024B2 (en) 1999-10-29 2017-06-06 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9320717B2 (en) 1999-10-29 2016-04-26 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9278074B2 (en) 1999-10-29 2016-03-08 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9056107B1 (en) 1999-10-29 2015-06-16 Purdue Pharma L.P. Controlled release hydrocodone formulations
US8980291B2 (en) 1999-10-29 2015-03-17 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9289391B2 (en) 2000-10-30 2016-03-22 Purdue Pharma L.P. Controlled release hydrocodone formulations
US10022368B2 (en) 2000-10-30 2018-07-17 Purdue Pharma L.P. Methods of manufacturing oral formulations
US8951555B1 (en) 2000-10-30 2015-02-10 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9023401B1 (en) 2000-10-30 2015-05-05 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9682077B2 (en) 2000-10-30 2017-06-20 Purdue Pharma L.P. Methods of providing analgesia
US9056052B1 (en) 2000-10-30 2015-06-16 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9060940B2 (en) 2000-10-30 2015-06-23 Purdue Pharma L.P. Controlled release hydrocodone
US9198863B2 (en) 2000-10-30 2015-12-01 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9205055B2 (en) 2000-10-30 2015-12-08 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9205056B2 (en) 2000-10-30 2015-12-08 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9669023B2 (en) 2000-10-30 2017-06-06 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9572805B2 (en) 2000-10-30 2017-02-21 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9572804B2 (en) 2000-10-30 2017-02-21 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9526724B2 (en) 2000-10-30 2016-12-27 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9504681B2 (en) 2000-10-30 2016-11-29 Purdue Pharma L.P. Controlled release hydrocodone formulations
US9517236B2 (en) 2000-10-30 2016-12-13 Purdue Pharma L.P. Controlled release hydrocodone formulations
US8557282B2 (en) 2001-11-13 2013-10-15 Lycored Bio Ltd. Extended release compositions comprising as active compound venlafaxine hydrochloride
US8062666B2 (en) 2001-11-13 2011-11-22 Lycored Bio Ltd. Extended release compositions comprising as active compound venlafaxine hydrochloride
EP1906935A2 (fr) * 2005-07-28 2008-04-09 Dr. Reddy's Laboratories Ltd. Compositions de venlafaxine à diffusion étendue
EP1906935A4 (fr) * 2005-07-28 2010-10-20 Reddys Lab Ltd Dr Compositions de venlafaxine à diffusion étendue
EA014262B1 (ru) * 2006-05-19 2010-10-29 Эгиш Дьёдьсердьяр Ньильваношан Мюкёдё Ресвеньтаршашаг Способ получения гранулированной массы
WO2007135470A1 (fr) * 2006-05-19 2007-11-29 EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság Procédé de préparation et de revêtement de surface de granulés
US9572803B2 (en) 2006-09-15 2017-02-21 Cima Labs Inc. Abuse resistant drug formulation
US9216176B2 (en) 2006-09-15 2015-12-22 Cima Labs Inc. Abuse resistant drug formulation
WO2011143119A1 (fr) * 2010-05-11 2011-11-17 Cima Labs Inc. Formes pharmaceutiques à libération prolongée résistantes aux alcools comprenant de la venlafaxine
JP2013526522A (ja) * 2010-05-11 2013-06-24 シマ ラブス インク． ベンラファキシンを含むアルコール耐性持続放出性剤形
US8927025B2 (en) 2010-05-11 2015-01-06 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended-release oral dosage forms
WO2014096124A1 (fr) * 2012-12-19 2014-06-26 Ratiopharm Gmbh Granules revêtus d'un film
US20160367502A1 (en) * 2012-12-19 2016-12-22 Ratiopharm Gmbh Film coated pellets
US9707224B2 (en) 2013-10-31 2017-07-18 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
US9757371B2 (en) 2013-10-31 2017-09-12 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
US10568881B2 (en) 2013-10-31 2020-02-25 Clexio Biosciences Ltd. Immediate release abuse-deterrent granulated dosage forms
US11207318B2 (en) 2013-10-31 2021-12-28 Clexio Biosciences Ltd. Immediate release abuse-deterrent granulated dosage forms
US11844796B2 (en) 2013-10-31 2023-12-19 Clexio Biosciences Ltd. Immediate release abuse-deterrent granulated dosage forms
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US11992468B2 (en) 2019-05-07 2024-05-28 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
CN114028577A (zh) * 2021-10-20 2022-02-11 珠海市东辰制药有限公司 一种二氧化硅丸芯及其制备方法

Also Published As

Publication number Publication date
BG109539A (bg) 2006-11-30
EP1677777A1 (fr) 2006-07-12
PL379541A1 (pl) 2006-10-02
DK1677777T3 (da) 2007-09-03
HUP0303382D0 (en) 2003-12-29
PT1677777E (pt) 2007-06-21
SK50442006A3 (sk) 2006-08-03
EA200600675A1 (ru) 2006-08-25
PL1677777T3 (pl) 2007-08-31
DE602004006009D1 (de) 2007-05-31
ES2285538T3 (es) 2007-11-16
HRP20070322T3 (en) 2007-09-30
AU2004280132A1 (en) 2005-04-21
RS20060252A (en) 2008-08-07
CN1882321A (zh) 2006-12-20
HUP0303382A2 (hu) 2005-08-29
HRP20060136A2 (en) 2006-06-30
CN1882321B (zh) 2011-06-08
NO20062082L (no) 2006-05-09
CZ2006269A3 (cs) 2006-07-12
IL174830A0 (en) 2008-04-13
IL174830A (en) 2010-04-15
EA009695B1 (ru) 2008-02-28
EP1677777B1 (fr) 2007-04-18
HK1098364A1 (en) 2007-07-20
RS52150B (en) 2012-08-31
AU2004280132B2 (en) 2009-10-22
SI1677777T1 (sl) 2007-10-31
DE602004006009T2 (de) 2008-01-10
UA82268C2 (uk) 2008-03-25
CY1106693T1 (el) 2012-05-23
ATE359771T1 (de) 2007-05-15

Similar Documents

Publication Publication Date Title
BG109539A (bg) Пелети съдържащи венлафаксин хидрохлорид
EP1557179B1 (fr) Forme posologuque analgesique ne pouvant pas être inhalé ou injecté
NL1009259C2 (nl) Fluoxetine-bevattende pellets die voorzien zijn van een tegen maagsap bestendige laag.
JPH09500914A (ja) 粉末被覆経口投与剤形
AU764280B2 (en) Process for the preparation of pellets with a content of up to 90 wt. per cent of a pharmaceutical active ingredient
CN1134108A (zh) 用于控释的新颗粒及含有该颗粒的药物制剂
CA2344372C (fr) Preparations et methodes de preparation pharmaceutiques a liberation controlee independante des effets alimentaires en doses unitaires multiples
CN101151026A (zh) O-去甲文拉法辛和巴泽昔芬联合产品及其应用
EP1938804A1 (fr) Préparation pharmaceutique comprenant un antagoniste de neurokinine
WO2004004692A1 (fr) Procedes de preparation de formulations de modafinil a administration orale
JP2007520547A (ja) ベンラファキシン塩酸塩の徐放性コーティングされた小型錠剤
CN112603900A (zh) 含[(4-羟基-1-甲基-7-苯氧基-异喹啉-3-羰基)-氨基]-乙酸的固体制剂
AU2017297117A1 (en) Oral pharmaceutical preparation having improved content uniformity, containing tamsulosin hydrochloride-containing extended release pellet
JP2001526206A (ja) 医薬用組成物
EP3892263A1 (fr) Forme pharmaceutique orale
WO2005034918A1 (fr) Comprimes contenant un ingredient pharmaceutique
CN112972396A (zh) 一种非布司他控释组合物及其制备方法
CN106491550B (zh) 一种含有喹硫平或其药学上可接受的盐的缓释片及其制备方法
AU2020100442B4 (en) Dosage form providing prolonged release of tapentadol phosphoric acid salt
WO2011096953A1 (fr) Formulation orale d'antidépresseur avec une charge réduite en excipients
OA12709A (en) Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxa-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-YL)-5-(2-pyridyl)quinzoline.
NZ562286A (en) Bi-layered modified release tablets for sustained release of guaifenesin combination drugs

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480033032.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 174830

Country of ref document: IL

Ref document number: 2006200600239

Country of ref document: RO

Ref document number: a 2006 00239

Country of ref document: RO

WWE Wipo information: entry into national phase

Ref document number: P20060136A

Country of ref document: HR

Ref document number: P-2006/0252

Country of ref document: YU

WWE Wipo information: entry into national phase

Ref document number: 12006500724

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2041/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PV2006-269

Country of ref document: CZ

Ref document number: 200600675

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2004791654

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 50442006

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 2004280132

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10953904

Country of ref document: BG

ENP Entry into the national phase

Ref document number: 2004280132

Country of ref document: AU

Date of ref document: 20041008

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004280132

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: PV2006-269

Country of ref document: CZ

Ref document number: 2004791654

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2004791654

Country of ref document: EP